- Home
- TRSG vs AKTX Comparison
TRSG vs AKTX Comparison
Compare TRSG & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRSG
- AKTX
- Stock Information
- Founded
- TRSG 1996
- AKTX N/A
- Country
- TRSG Singapore
- AKTX United States
- Employees
- TRSG N/A
- AKTX N/A
- Industry
- TRSG
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- TRSG
- AKTX Health Care
- Exchange
- TRSG NYSE
- AKTX Nasdaq
- Market Cap
- TRSG 27.0M
- AKTX 35.7M
- IPO Year
- TRSG 2024
- AKTX N/A
- Fundamental
- Price
- TRSG $1.76
- AKTX $1.08
- Analyst Decision
- TRSG
- AKTX
- Analyst Count
- TRSG 0
- AKTX 0
- Target Price
- TRSG N/A
- AKTX N/A
- AVG Volume (30 Days)
- TRSG 4.6K
- AKTX 22.7K
- Earning Date
- TRSG 05-14-2025
- AKTX 08-18-2025
- Dividend Yield
- TRSG N/A
- AKTX N/A
- EPS Growth
- TRSG N/A
- AKTX N/A
- EPS
- TRSG N/A
- AKTX N/A
- Revenue
- TRSG $12,810,249.00
- AKTX N/A
- Revenue This Year
- TRSG N/A
- AKTX N/A
- Revenue Next Year
- TRSG N/A
- AKTX N/A
- P/E Ratio
- TRSG N/A
- AKTX N/A
- Revenue Growth
- TRSG N/A
- AKTX N/A
- 52 Week Low
- TRSG $1.00
- AKTX $0.85
- 52 Week High
- TRSG $4.57
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- TRSG N/A
- AKTX 41.09
- Support Level
- TRSG N/A
- AKTX $1.10
- Resistance Level
- TRSG N/A
- AKTX $1.15
- Average True Range (ATR)
- TRSG 0.00
- AKTX 0.03
- MACD
- TRSG 0.00
- AKTX 0.00
- Stochastic Oscillator
- TRSG 0.00
- AKTX 10.00
About TRSG TUNGRAY TECHNOLOGIES INC
Tungray Technologies Inc is an engineer-to-order company that provides custom industrial manufacturing solutions to original equipment manufacturers in the semiconductor, printer, electronics, and home appliance industries. It predominantly generates revenue through the manufacture of custom industrial manufacturing solutions, direct drive and linear DC motors, and induction welding equipment. Geographically, the company generates a majority of its revenue from Singapore and the rest from China.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.